WO2004112851A1 - Hydrogel compositions comprising enzymes - Google Patents
Hydrogel compositions comprising enzymes Download PDFInfo
- Publication number
- WO2004112851A1 WO2004112851A1 PCT/GB2004/002696 GB2004002696W WO2004112851A1 WO 2004112851 A1 WO2004112851 A1 WO 2004112851A1 GB 2004002696 W GB2004002696 W GB 2004002696W WO 2004112851 A1 WO2004112851 A1 WO 2004112851A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrogel
- layer
- wound
- wound dressing
- oxidase
- Prior art date
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 150
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 52
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims description 31
- 239000000463 material Substances 0.000 claims abstract description 35
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 claims abstract description 32
- 229920000642 polymer Polymers 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000002243 precursor Substances 0.000 claims abstract description 4
- 239000007787 solid Substances 0.000 claims abstract description 4
- 229940088598 enzyme Drugs 0.000 claims description 48
- 239000000499 gel Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- -1 vinyl alcohols Chemical class 0.000 claims description 18
- 239000002250 absorbent Substances 0.000 claims description 16
- 230000002745 absorbent Effects 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000000178 monomer Substances 0.000 claims description 14
- 102000016938 Catalase Human genes 0.000 claims description 12
- 108010053835 Catalase Proteins 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 239000004014 plasticizer Substances 0.000 claims description 8
- 102000003992 Peroxidases Human genes 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 230000002503 metabolic effect Effects 0.000 claims description 5
- 108010088842 Fibrinolysin Proteins 0.000 claims description 4
- 108010015776 Glucose oxidase Proteins 0.000 claims description 4
- 239000004366 Glucose oxidase Substances 0.000 claims description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229940116332 glucose oxidase Drugs 0.000 claims description 4
- 235000019420 glucose oxidase Nutrition 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 229940012957 plasmin Drugs 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 102000004316 Oxidoreductases Human genes 0.000 claims description 3
- 108090000854 Oxidoreductases Proteins 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 229920006254 polymer film Polymers 0.000 claims description 3
- 230000000379 polymerizing effect Effects 0.000 claims description 3
- 108010030844 2-methylcitrate synthase Proteins 0.000 claims description 2
- 108010009924 Aconitate hydratase Proteins 0.000 claims description 2
- 108010073975 Brinolase Proteins 0.000 claims description 2
- 108010004032 Bromelains Proteins 0.000 claims description 2
- 108010035722 Chloride peroxidase Proteins 0.000 claims description 2
- 108010089254 Cholesterol oxidase Proteins 0.000 claims description 2
- 108010000659 Choline oxidase Proteins 0.000 claims description 2
- 102100034229 Citramalyl-CoA lyase, mitochondrial Human genes 0.000 claims description 2
- 108010071536 Citrate (Si)-synthase Proteins 0.000 claims description 2
- 102000006732 Citrate synthase Human genes 0.000 claims description 2
- 108060005980 Collagenase Proteins 0.000 claims description 2
- 102000029816 Collagenase Human genes 0.000 claims description 2
- 102100039868 Cytoplasmic aconitate hydratase Human genes 0.000 claims description 2
- 102000004674 D-amino-acid oxidase Human genes 0.000 claims description 2
- 108010003989 D-amino-acid oxidase Proteins 0.000 claims description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 2
- 108010015133 Galactose oxidase Proteins 0.000 claims description 2
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 claims description 2
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 claims description 2
- 102000005548 Hexokinase Human genes 0.000 claims description 2
- 108700040460 Hexokinases Proteins 0.000 claims description 2
- 102000011845 Iodide peroxidase Human genes 0.000 claims description 2
- 108010036012 Iodide peroxidase Proteins 0.000 claims description 2
- 108020003285 Isocitrate lyase Proteins 0.000 claims description 2
- 108090000769 Isomerases Proteins 0.000 claims description 2
- 102000004195 Isomerases Human genes 0.000 claims description 2
- 102100038609 Lactoperoxidase Human genes 0.000 claims description 2
- 108010023244 Lactoperoxidase Proteins 0.000 claims description 2
- 108010026217 Malate Dehydrogenase Proteins 0.000 claims description 2
- 102000013460 Malate Dehydrogenase Human genes 0.000 claims description 2
- 108020004687 Malate Synthase Proteins 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims description 2
- 108010014251 Muramidase Proteins 0.000 claims description 2
- 102000003896 Myeloperoxidases Human genes 0.000 claims description 2
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
- 108010063734 Oxalate oxidase Proteins 0.000 claims description 2
- 102000001105 Phosphofructokinases Human genes 0.000 claims description 2
- 108010069341 Phosphofructokinases Proteins 0.000 claims description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 claims description 2
- 108010038555 Phosphoglycerate dehydrogenase Proteins 0.000 claims description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 claims description 2
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 claims description 2
- 102000013009 Pyruvate Kinase Human genes 0.000 claims description 2
- 108020005115 Pyruvate Kinase Proteins 0.000 claims description 2
- 108010042687 Pyruvate Oxidase Proteins 0.000 claims description 2
- 108010023197 Streptokinase Proteins 0.000 claims description 2
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 2
- 108090000631 Trypsin Proteins 0.000 claims description 2
- 102000004142 Trypsin Human genes 0.000 claims description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000001323 aldoses Chemical class 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 229940086617 aspergillus flavus var. oryzae protease Drugs 0.000 claims description 2
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 235000019835 bromelain Nutrition 0.000 claims description 2
- 229960002424 collagenase Drugs 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical class OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 108010062584 glycollate oxidase Proteins 0.000 claims description 2
- 108010018734 hexose oxidase Proteins 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 229940057428 lactoperoxidase Drugs 0.000 claims description 2
- 229960000274 lysozyme Drugs 0.000 claims description 2
- 239000004325 lysozyme Substances 0.000 claims description 2
- 235000010335 lysozyme Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 2
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 claims description 2
- OMNKZBIFPJNNIO-UHFFFAOYSA-N n-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=O)CC(C)(C)NC(=O)C=C OMNKZBIFPJNNIO-UHFFFAOYSA-N 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 235000019833 protease Nutrition 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 108060006633 protein kinase Proteins 0.000 claims description 2
- 108010001816 pyranose oxidase Proteins 0.000 claims description 2
- 229960004533 streptodornase Drugs 0.000 claims description 2
- 229960005202 streptokinase Drugs 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 150000003641 trioses Chemical class 0.000 claims description 2
- 239000012588 trypsin Substances 0.000 claims description 2
- 229960001322 trypsin Drugs 0.000 claims description 2
- 229960005356 urokinase Drugs 0.000 claims description 2
- 229920001567 vinyl ester resin Polymers 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 abstract description 8
- 229920002401 polyacrylamide Polymers 0.000 abstract description 2
- 206010052428 Wound Diseases 0.000 description 83
- 208000027418 Wounds and injury Diseases 0.000 description 83
- 239000010410 layer Substances 0.000 description 71
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 21
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 229920002635 polyurethane Polymers 0.000 description 13
- 239000004814 polyurethane Substances 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229940076788 pyruvate Drugs 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical class [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000000416 exudates and transudate Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 3
- 150000003926 acrylamides Chemical class 0.000 description 3
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 125000004386 diacrylate group Chemical group 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229910003002 lithium salt Inorganic materials 0.000 description 3
- 159000000002 lithium salts Chemical class 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000012956 1-hydroxycyclohexylphenyl-ketone Substances 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NYUTUWAFOUJLKI-UHFFFAOYSA-N 3-prop-2-enoyloxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCOC(=O)C=C NYUTUWAFOUJLKI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229920005830 Polyurethane Foam Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- MQDJYUACMFCOFT-UHFFFAOYSA-N bis[2-(1-hydroxycyclohexyl)phenyl]methanone Chemical compound C=1C=CC=C(C(=O)C=2C(=CC=CC=2)C2(O)CCCCC2)C=1C1(O)CCCCC1 MQDJYUACMFCOFT-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 229940116871 l-lactate Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000011496 polyurethane foam Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- ZDQNWDNMNKSMHI-UHFFFAOYSA-N 1-[2-(2-prop-2-enoyloxypropoxy)propoxy]propan-2-yl prop-2-enoate Chemical compound C=CC(=O)OC(C)COC(C)COCC(C)OC(=O)C=C ZDQNWDNMNKSMHI-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- XLPJNCYCZORXHG-UHFFFAOYSA-N 1-morpholin-4-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCOCC1 XLPJNCYCZORXHG-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960003920 ***e Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960003704 framycetin Drugs 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229920003175 pectinic acid Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- VSFOXJWBPGONDR-UHFFFAOYSA-M potassium;3-prop-2-enoyloxypropane-1-sulfonate Chemical compound [K+].[O-]S(=O)(=O)CCCOC(=O)C=C VSFOXJWBPGONDR-UHFFFAOYSA-M 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
Definitions
- the present invention relates to hydrogel compositions comprising active enzymes.
- the invention also relates to methods of manufacture of such compositions, and the use of such compositions in wound dressings.
- Hydrogel wound dressings in which the wound contacting layer comprises a hydrogel, are advantageous because wound exudate does not generally dry and consolidate with hydrogel. Consequently, the removal of a hydrogel dressing is usually neither painful nor detrimental to the healing process. Hydrogel dressings are particularly desirable for the treatment of burns. There can be difficulties in handling the structurally weak gels in high speed manufacturing processes, and in clinical practice. For this reason, the hydrogel layer may be laminated to a support layer, for example a plastic film or a textile layer.
- the natural hydrogels include gelatins, pectins, and hyaluronic acid and its derivatives.
- Semi-synthetic hydrogels include modified celluloses and modified starches.
- Synthetic hydrogel- forming polymers suitable for use in wound dressings include certain polyurethanes, polyacrylates, polyacrylamides, and polyvinylpyrrolidones. Synthetic hydrogels have the advantage that they can be prepared as a liquid prepolymerisation mixture of controlled viscosity that can be applied to a suitable substrate, and then polymerised on the substrate to provide a desired hydrogel laminate.
- US-A-5160328 describes a dressing having a wound contacting layer of a polyurethane hydrogel.
- the polyurethane gel comprises from 0% to 90% of polyhydric alcohol such as polypropylene glycol, from 6% to 60% by weight of an isocyanate-terminated prepolymer, from 4% to 40% by weight of a polyethylene oxide based diamine, and the balance water.
- the hydrogel layer is disposed on a support layer that provides mechanical support for the relatively weak hydrogel.
- EP-A-0610056 describes a hydrogel dressing comprising a wound contacting layer of polyvinylpyrrolidone, which has been cross-linked by irradiation, and which is applied to a substrate.
- the hydrogel facing surface of the substrate comprises fibers projecting into the hydrogel.
- the hydrogel is cross-linked on the substrate and thereby firmly anchored thereto.
- WOOO/07638 describes polyacrylate hydrogel materials suitable for use as the wound contacting layer of wound dressings.
- WO02/38097 describes wound dressings having a layer of hydrogel coated onto the wound facing layer of an apertured polymer film support sheet.
- WO97/02811 describes a hydrogel patch for the measurement of blood glucose.
- the glucose drawn into the patch undergoes a reaction with a glucose oxidase in the gel, and the hydrogen peroxide thereby released is used for electrochemical determination of the glucose concentration.
- the preferred gel is a cross-linked polyethylene oxide.
- the cross-linking can be carried out with a bis acrylamide in the presence of the glucose oxidase.
- US-A-5648252 describes incorporating enzymes into insoluble hydrogels formed by combining an anionic hydrogel with a cationic hydrogel.
- WO00/78332 describes incorporating fish serine proteases into medicinal compositions, including gels.
- the present invention provides a wound dressing comprising a synthetic hydrogel material, wherein an active enzyme is dispersed in the synthetic hydrogel material.
- the wound dressing of the present invention further comprises a support and the synthetic hydrogel material containing the dispersed active enzyme is coated onto the support.
- the present invention provides a method of making a wound dressing comprising the steps of: preparing a hydrogel premix comprising a synthetic hydrogel polymer precursor and an enzyme; followed by polymerising the premix to produce a synthetic hydrogel material having an active enzyme dispersed therein.
- the method further comprises applying a layer of the premix to a solid support; and the step of polymerising the premix is carried out on the support to produce a layer of the synthetic hydrogel material containing an active enzyme on the support.
- the present invention further provides the use of a wound dressing according to the present invention for the preparation of a dressing for application to a wound.
- the present invention provides a method of treatment of a wound comprising the step of applying a wound dressing in accordance with the present invention to the surface of the wound
- the Support may be any structure having stiffness or tensile strength greater than that of the hydrogel layer.
- the support is in the form of a sheet material, usually a flat sheet material.
- the support is made from a material that is not water soluble or water swellable.
- the support sheet may be formed from a thermoplastic film-forming polymer.
- the polymer is conformable but not substantially elastomeric.
- Suitable polymers include, but are not limited to, polyolefins such as polyethylene and polypropylene; polyesters; polyamides such as nylons; fluoropolymers such as polyvinylidene fluoride (PVDF) or polytetrafluoroethylene (PTFE); olefin copolymers such as ethylene vinyl alcohol (EVA), and mixtures and laminates thereof.
- the film has a thickness by weight (ASTM E252-84) of from 10 to 200 micrometers, more preferably from 25 to 100 micrometers.
- the support may be continuous or interrupted.
- the support sheet may be a polymer film, which may be apertured to provide liquid permeability.
- the support sheet may comprise, or consist essentially of, a woven, nonwoven or knitted fabric.
- the support sheet is adapted to block or restrict passage of liquid from a back surface to a wound facing surface of the support sheet. That is to say, the support sheet allows fluid to pass through the support sheet from the wound site, but blocks or restricts flow of the fluid back through the support sheet onto the wound (also known as wet-back).
- Such non-wetting support sheets may for example be made from porous non-woven fabrics comprising a layer of hydrophobic fibers, or having a hydrophobic finish applied to at least the outer surface thereof.
- the support sheet has greater liquid permeability to the flow of liquid away from the wound facing surface than to the flow of liquid towards the wound facing surface.
- the support sheet is formed from a substantially liquid-impermeable sheet material provided with tapered capillaries, each capillary having a base substantially in the plane of the wound facing surface of the support sheet and an apical opening remote from the wound facing surface of the support sheet and preferably in contact with the hydrogel and/or the absorbent layer.
- the conical capillaries provide rapid one-way wicking of fluid from the front of the support sheet, with minimal wet-back.
- Support sheets of this type are described in GB-A-1526778, the entire content of which is incorporated herein by reference. Support sheets of this type may be manufactured, for example, by embossing or vacuum perforation of a liquid-impermeable thermoplastic film.
- the density of the capillaries is from 10 to 400 per cm 2 , more preferably from 50 to 200 per cm 2 .
- the open area of the support sheet is from 5 to 50% of the total area, more preferably from 10 to 25% of the total area.
- enzyme refers to a polypeptide having catalytic effect in a metabolic reaction. It encompasses both therapeutic enzymes and diagnostic enzymes, but it does not encompass growth factors.
- Suitable enzymes may be selected from the group consisting of:
- antimicrobial enzymes such as lysozyme
- oxidase enzymes such as lactate oxidase, glucose oxidase, hexose oxidase, cholesterol oxidase, galactose oxidase, pyranose oxidase, choline oxidase, pyruvate oxidase, oxalate oxidase, glycollate oxidase and D-aminoacid oxidases;
- peroxidase enzymes such as lactoperoxidase, horseradish peroxidase, iodide peroxidase, chloride peroxidase and myeloperoxidase;
- Matrix forming and degrading enzymes including proteinases and proteases, for example Streptokinase, collagenase and streptodornase , bromelain, plasmin and trypsin, Urokinase, plasmin, brinolase, tissue plasminogen activator, Factor Xllla, thrombin, Von Willibrand factor,
- Metabolic enzymes for example Hexokinase, Phosphoglucose isomerase, phosphofructokinase, Aldose, Triose, phosphate isomerase, glyceraldehydes 3- phosphate dehydrogenase, phosphoglycerate kinase, phosphoglycerol mutase, enolase, pyruvate kinase, Citrate synthase, Aconitase, Isocitrate lyase, malate synthase, malate dehydrogenase;
- the enzymes comprise lactate oxidase, for the following reasons.
- Oxygen is a prerequisite for the formation of chemical energy within living cells.
- the tissue will preferentially use the glycolytic pathway to generate energy in the form of adenosine triphosphate (ATP), since the amount of oxygen is limiting.
- ATP adenosine triphosphate
- Pyruvate is converted to lactate by lactate dehydrogenase, in the process generating two molecules of ATP per molecule of pyruvate hydrolysed.
- lactate dehydrogenase in the process generating two molecules of ATP per molecule of pyruvate hydrolysed.
- only a small fraction of the potential energy content of glucose is released by anaerobic conversion into lactate; much more energy can be released by the oxidative decarboxylation of pyruvate via the citric acid cycle.
- Lactate is in effect a metabolic "dead-end" in the mammalian body, as it must be converted back into pyruvate before it can be metabolised. In mammals, this reaction is only performed in the liver. Consequently, in wounds, lactate concentrations often rise to levels which are detrimental to the healing process. In particular, the presence of large amount of lactic acid in the wound causes a severe drop in the pH of the wound and thus slows down the healing process; (the ideal pH for the healing process to take place in the wound is thought to be around 6.0). In addition, high levels of lactic acid upset the redox balance of the wound, and impair metabolic balance in other ways.
- the activity of the dressings can be specified in terms of activity units per gram of the dressing.
- One unit will remove 1.0 ⁇ mol of L-lactate per minute at pH6.5 at 37°C.
- one unit of lactate oxidase activity is the amount needed to oxidize 1.0 ⁇ mol of L-lactate to pyruvate and H 2 O 2 per minute at pH6.5 at 37°C.
- the activity (e.g. lactate oxidase activity) of the dressings is from about 0.001 units/g to about 100 units/g, more preferably from about 0.01 units/g to about 10 units/g, and most preferably from about 0.1 units/g to about 1 unit/g.
- the compound or reagent comprises a lactate oxidase enzyme.
- Lactate oxidase may be derived from any organism or may be partially or wholly synthetic. Suitable lactate oxidase species are present in both prokaryotes and eukaryotes. From the point of view of expense, prokaryote-derived enzymes will be preferred, although eukaryote enzymes, preferably mammalian or human, are less likely to cause immunogenic reactions in the wound site. Human lactate oxidase is most preferable.
- each gram of the dressings according to the present invention contains from about 0.1 ng to about 1mg of lactate oxidase, more preferably from about 1ng to about 100ng of lactate oxidase.
- Lactate oxidase enzyme that have been engineered to possess advantageous properties over the wild type species may also be used according to the present invention.
- enzymes may be modified by site-directed mutagenesis to accelerate the rate at which they metabolise lactate or to reduce the immunogenicity of the protein.
- Lactate oxidase acts to catalytically convert lactic acid into pyruvic acid that will diffuse into the environment of the wound, where it may be utilised as an energy source by the cells of the wound through its oxidative carboxylation as part of the citric acid cycle.
- the availability of this extra energy source will allow the cells of the wound to grow more quickly.
- the pH of the wound environment will increase as the lactic acid concentration in the wound falls.
- the oxygen needed for lactate oxidase reaction comes from the environment of the wound and from the atmosphere itself.
- the hydrogen peroxide generated as a by-product of this reaction of lactate oxidase with oxygen may spontaneously decompose to release oxygen back into the wound.
- the hydrogen peroxide may also be beneficial to the wound healing process.
- hydrogen peroxide is a bactericidal agent, acting to inhibit the growth of microbes on the wound surface, thereby minimising the risk of development of clinical infections in the wound.
- this chemical acts to minimise the build-up of chemical odours developing from microbial growth in the wound.
- the higher the lactate concentration in the wound the greater the activity of lactate oxidase in the wound dressing or implant that will result. Consequently, the system is self-regulating.
- Additional compounds may also be coupled in particular to the oxidase enzymes used in of the present invention.
- a compound can be used that accelerates the reduction of H 2 O 2 into H 2 O and molecular oxygen.
- a suitable enzyme that catalyses this process is the catalase enzyme. The reaction in the presence of lactate oxidase and catalase is set out below.
- catalase as a coupled enzyme has the advantage that local oxygen levels in the wound environment may be boosted, causing a concomitant increase in growth of cells in the environment of the wound.
- Catalase enzyme may be obtained from any source, as discussed above for lactate oxidase.
- Potato homogenate is a particularly good source of catalase.
- Catalase activity is generally defined such that one unit will decompose 1.O ⁇ mol of H 2 O 2 per minute at pH 7.0 at 25°C, while the H 2 O 2 concentration falls from 10.3 to 9.2mM.
- the catalase activity per gram of the wound dressings of the present invention is within one of the preferred ranges specified above for the lactate oxidase activity-
- the activity of commercially available catalase varies from about 1000 units/mg to about 50,000 units/mg. It follows that the amount of catalase used to make the wound dressings of the invention is preferably about 0.01 ng to about 10ng/gram of the hydrogel dry weight.
- Indicator systems that are responsive to the concentration of various substances such as hydrogen peroxide in a wound may also be associated with the wound dressing or implant of the present invention.
- the indicated concentration of H 2 O 2 produced by the reaction between lactate oxidase and lactic acid gives an indication of the concentration of lactate initially present in the wound environment. This will give a physician useful information about the metabolic condition of the wound, for example an indication of the degree of hypoxia.
- the indicator systems may comprise a redox indicator compound, which is usually activated by a peroxidase enzyme in the presence of hydrogen peroxide.
- the indicator compound is a chromogenic compound.
- Suitable chromogenic substrates suitable as coupled indicators of lactate concentration include the following, along with the colour produced upon oxidation by H 2 O 2 .
- ABTS (2,2'-azino-bis-(3-ethyibenzthiazoline- ⁇ -sulphonic acid) [green]; OPD (o- phenylened ⁇ amine) [orange]; TMB (3,3'-5,5'-tetramethylbenzidine) [blue]; O- dianisidine [orange]; 5AS (5-aminosalicylic acid) [brown]; DAB (3,3'- diaminobenz ⁇ dine) [brown]; AEC (3-amino-9-ethylcarbazole) [blue]; 4C1 N (4- chloro-l-naphthol) [blue]. All of these indicator compounds are available from Sigma Chemical Company.
- a means of oxidation of the compound must also be present in the dressing or implant. Any means of oxidation may be used that can be coupled stoichiometrically to the amount of hydrogen peroxide present in the wound.
- a peroxidase enzyme may be incorporated into the device, so causing the oxidation of an indicator compound. This reaction is shown below:
- the means of oxidation of the indicator compound comprises a peroxidase enzyme, more preferably horseradish peroxidase. Suitable concentrations of peroxidase enzyme and indicator can readily be determined by the person skilled in the art.
- hydrogel layer refers to thin, two-dimensional layer, preferably consisting essentially of the hydrogel composition. It may be a substantially unitary layer, and it may have substantially constant thickness. In certain embodiments, the hydrogel layer is coextensive with the support. The advantages of the invention can be achieved with a thin hydrogel layer, which minimises the cost of the dressing.
- the hydrogel layer typically has a dry basis weight of from about 1 to about 2000g/m 2 , for example about 5 to about 1000 g/m 2 , or from 10 about to about 500g/m 2 , or from about 10 to about 200g/m 2 , or from about 10 to about 100g/m 2 , or from 10 about to about 50g/m 2 .
- the hydrogel layer may be continuous or discontinuous. Continuous hydrogel layers extend over and cover any apertures in the support. Such continuous layers provide the advantage of temporarily blocking (gel blocking) the passage of wound fluid through the support until the hydrogel is saturated. This helps to prevent drying out of wounds having low rates of exudate production.
- the hydrogel layer is apertured. In some embodiments it is apertured in register with apertures in the support so as not to obstruct passage of fluid through the support even when the hydrogel is fully swelled. In these embodiments, there is substantially no hydrogel initially present in or covering the apertures of the support.
- hydrogel refers generally to materials that interact with wound fluid under physiological conditions to form a hydrated gel at the wound surface. That is to say, the hydrogel polymer forms a gel with water under physiological conditions of temperature and pH. Such hydrogel layers are formed by medically acceptable synthetic macromolecular materials that have the ability to swell and absorb fluid while maintaining a strong integral structure.
- the hydrogel material is normally substantially insoluble in water under physiological conditions, whereby the hydrogel is not washed away by the wound fluid.
- the hydrogel may be may be bioabsorbable. That is to say, it may undergo full degradation and resorption in vivo in the mammalian body.
- a suitable composition for the hydrogel layers of the present invention comprises a plasticised three-dimensional matrix of cross-linked polymer molecules. Such polymers can have sufficient structural integrity to be self-supporting even at very high levels of internal water content, with sufficient flexibility to conform to the surface contours of the human skin.
- Exemplary insoluble gels include polyurethane gels, certain cross-linked polyacrylate gels, and gels formed by polymerizing vinyl alcohols, vinyl esters, vinyl ethers, N-vinyl pyrrolidone, PLURONIC (Registered Trade Mark) (block polyethylene glycol, block polypropylene glycol) polystyrene-, maleic acid, and mixtures thereof.
- polyurethane herein refers to a polymer having a plurality (preferably at least 10, 20 or 100) urethane and/or urea linkages in the main polymer chain.
- polyacrylate herein refers to a polymer wherein the main polymer chain is formed by polymerising or copolymerising one or more carboxy vinyl monomers (acrylates or acrylate derivatives), for example one or more monomers selected from the group consisting of meth(acrylic) acid, acrylamide, N-substituted acrylamides, acylamidopropane sulphonic acid, NN- dimethylacrylamide diacetone acrylamide, acryloyl morpholine, and mixtures thereof.
- carboxy vinyl monomers acrylates or acrylate derivatives
- the gel adheres strongly to the surface of the support material to resist washing off by wound fluid.
- the gel may be directly coated or chemically covalently bonded to the support material.
- the hydrogel layer comprises a hydrogel material selected from polyurethane gels, and polyacrylates, i.e. polymers of acrylates and acrylate derivatives such as modified acrylamides and mixtures thereof.
- the gel- forming polymer of the hydrogel layer consists essentially of polyurethane or polyacrylate
- the hydrogel layer comprises a hydrogel material of the kind described in WOOO/07638 or WO00/065143, the entire contents of which are incorporated herein by reference.
- the gels are cross-linked, and the cross-linking may be either covalent or ionic.
- the hydrogel material further comprises from 5 to 50% by weight on a dry weight basis of one or more humectants such as glycerol.
- the hydrogel composition used in the present invention typically consists essentially of a cross-linked hydrophilic polymer of a hydrophilic monomer and optionally one or more comonomers, together with water and/or one or more organic plasticisers, and optionally together with one or more additives selected from surfactants, polymers, pH regulators, bioactive compounds and mixtures thereof, with less than about 10% by weight of other additives.
- the hydrophilic acrylate monomer may be one or more ionic monomers.
- the hydrophilic monomer may be a mixture of anionic and cationic monomers, typically in substantially equimolar amounts.
- the one or more ionic monomers may for example be selected from: 2-acrylamido-2-methylpropane sulphonic acid or an analog thereof or one of its salts (e.g. an ammonium or alkali metal salt such as a sodium, potassium or lithium salts); acrylic acid or an analogue thereof or one of its salts (e.g. an alkali metal salt such as a sodium, potassium or lithium salt); and/or a polymerisable sulphonate or a salt thereof (e.g.
- an alkali metal salt such as a sodium, potassium or lithium salt
- acrylic acid 3-sulphopropyl ester or an analogue thereof, or a salt thereof.
- analogue in this context refers particularly to substituted derivatives of 2- acrylamido-2-methylpropane sulphonic acid, of acrylic acid or of acrylic acid (3- sulphopropyl) ester.
- a particularly suitable ionic monomer is a sodium salt of 2-acrylamido-2- methylpropane sulphonic acid, commonly known as NaAMPS and/or acrylic acid (3-sulphopropyl) ester potassium salt, commonly known as SPA or SPAK.
- the hydrophilic acrylate monomer may alternatively or additionally be non-ionic, for example it may be selected from acrylamide or a mono- or di-N-alkylacrylamide or an analog thereof.
- non-ionic water soluble monomers containing an alkyl or substituted alkyl group linked to a carbon-carbon double bond via an amido or alkylamido (-CO.NH- or -CO.NR-) function.
- Examples of such analogs include diacetone acrylamide (N-1,1- dimethyl-3-oxobutyl-acrylamide), vinyl lactams, N-alkylated acrylamides, N,N- dialkylated acrylamides, N-vinyl pyrrolidone, N-acryloyl morphoiine and any mixture thereof, particularly N-acryloyl morphoiine.
- cross-linking agents are suitably used to provide the necessary mechanical stability and insolubility to the hydrogel.
- the amount of cross-linking agent required will suitably from about 0.01% to about 0.5%, particularly from about 0.05% to about 0.4%, most particularly from about 0.08% to about 0.3%, by weight of the total polymerisation reaction mixture.
- Typical cross-linkers for use in cross-linking of polyacrylates useful in the present invention include tripropylene glycol diacrylate, ethylene glycol dimethacrylate, triacrylate, polyethylene glycol diacrylate (polyethylene glycol (PEG) molecular weight between about 100 and about 4000, for example PEG400 or PEG600), and methylene bis acrylamide.
- the one or more organic plasticisers when present, may suitably comprise any of the following either alone or in combination: at least one polyhydric alcohol (such as glycerol, polyethylene glycol, or sorbitol), at least one ester derived therefrom, at least one polymeric alcohol (such as polyethylene oxide) and/or at least one mono- or poly-alkylated derivative of a polyhydric or polymeric alcohol (such as alkylated polyethylene glycol).
- Glycerol is the preferred plasticiser.
- An alternative preferred plasticiser is the ester derived from boric acid and glycerol.
- the organic plasticiser may comprise up to about 45% by weight of the hydrogel composition.
- the hydrogel compositions may comprise Non-ionic Surfactants, Anionic Surfactants, Cationic Surfactants, or mixtures thereof.
- the total amount of surfactant, if present, is suitably up to about 10% by weight of the hydrogel composition, preferably from about 0.05% to about 4% by weight.
- the hydrogel may be a polyurethane gel, for example a gel formed by reaction of an isocyanate prepolymer with a chain extending compound such as a diamine or water.
- the hydrogel material may be formed from an aqueous mixture including from about 0% to about 90% by weight polyhydric alcohol; from about 6% to about 60% by weight aliphatic diisocyanate- terminated prepolymer; from about 4% to about 40% by weight polyethylene oxide-based polyamine; up to about 2% by weight sodium chloride; and the balance water.
- a more suitable hydrogel composition for forming the polyurethane hydrogel layer comprises from about 15% to about 30% by weight of a polyhydric alcohol selected from a group consisting of polypropylene glycol, polyethylene glycol and glycerine, from about 8% to about 14% by weight isophorone- diisocyanate-terminated prepolymer, from about 5% to about 10% by weight polyethylene oxide-based diamine, up to about 1% by weight of a salt, and the remaining percentage water.
- Suitable isocyanate capped prepolymers for the production of polyurethane hydrogels, and methods of manufacture thereof are described in EP-A-0335669 and WO9902587, the entire contents of which are incorporated herein by reference.
- the hydrogel composition used in the present invention may include one or more additional ingredients, which may be added to the pre-polymerisation mixture or the polymerised product.
- additional ingredients are selected from the group consisting of water, organic plasticisers, surfactants, polymers, pH regulators, colorants and mixtures thereof.
- the polymers can for example be biopolymers, such as gelatin, pectin or hyaluronic acid.
- the enzyme may be covalently bonded to the polymer chain of the synthetic hydrogel material.
- the enzyme is frequently partially or completely copolymerized with the synthetic hydrogel material.
- the hydrogel layer may be provided on the wound facing surface of the wound dressing according to the present invention.
- the hydrogel then provides a wound friendly, soft, non-adherent and therapeutic wound contacting surface to the dressing.
- the hydrogel layer is provided on the back surface of the support sheet, opposite the wound facing surface.
- the dressing may further comprise a backing layer over the back face of the support sheet.
- the backing layer supports the support sheet and any optional intermediate absorbent layer and suitably provides a barrier to passage of microorganisms through the dressing.
- the backing layer may extend beyond at least one edge of the hydrogel layer to provide an adhesive-coated margin adjacent to the said edge for adhering the dressing to a surface, such as to the skin of a patient adjacent to the wound being treated.
- An adhesive-coated margin may extend around all sides of the hydrogel layer, so that the dressing is a so- called island dressing. However, it is not necessary for there to be any adhesive- coated margin.
- the backing layer is normally substantially liquid-impermeable.
- the backing sheet is preferably semipermeable. That is to say, the backing sheet is preferably permeable to water vapour, but not permeable to liquid water or wound exudate.
- the backing sheet is also microorganism-impermeable.
- Suitable continuous conformable backing sheets will preferably have a moisture vapor transmission rate (MVTR) of the backing sheet alone of 300 to 5000 g/m 2 /24hrs, preferably 500 to 2000 g/m 2 /24hrs at 37.5"C at 100% to 10% relative humidity difference.
- the backing sheet thickness is preferably in the range of 10 to 1000 micrometers, more preferably 100 to 500 micrometers.
- the MVTR of the dressing according to the present invention as a whole is lower than that of the backing sheet alone, because the hydrogel layer and support sheet partially obstruct moisture transfer through the dressing.
- the MVTR of the dressing (measured across the island portion of the dressing) is from 20% to 80% of the MVTR of the backing sheet alone, more preferably from 20% to 60% thereof, and most preferably about 40% thereof. It has been found that such moisture vapor transmission rates allow the wound under the dressing to heal under moist conditions without causing the skin surrounding the wound to macerate.
- Suitable polymers for forming the backing sheet include polyurethanes and poly alkoxyalkyl acrylates and methacrylates such as those disclosed in GB-A- 1280631.
- the backing sheet comprises a continuous layer of a high density blocked polyurethane foam that is predominantly closed-cell.
- a suitable backing sheet material is the polyurethane film available under the Registered Trade Mark ESTANE 5714F.
- the adhesive (where present) layer should be moisture vapor transmitting and/or patterned to allow passage of water vapor therethrough.
- the adhesive layer is preferably a continuous moisture vapor transmitting, pressure-sensitive adhesive layer of the type conventionally used for island-type wound dressings, for example, a pressure sensitive adhesive based on acrylate ester copolymers, polyvinyl ethyl ether and polyurethane as described for example in GB-A-1280631.
- the basis weight of the adhesive layer is preferably 20 to 250 g/m 2 , and more preferably 50 to 150 g/m 2 . Polyurethane-based pressure sensitive adhesives are preferred.
- the area of the optional absorbent layer is typically in the range of from 1cm 2 to 200cm 2 , more preferably from 4cm 2 to 100cm 2 .
- the optional absorbent layer may be any of the layers conventionally used for absorbing wound fluids, serum or blood in the wound healing art, including foams, sponges, gauzes, and nonwoven fabrics, and combinations thereof. Superabsorbents or hydrogels may be dispersed in the optional absorbent layer to improve liquid absorbency and retention.
- the absorbent layer comprises a layer of absorbent foam, such as an open celled hydrophilic polyurethane foam prepared in accordance with EP-A-0541391, the entire content of which is expressly incorporated herein by reference.
- the absorbent layer may be a nonwoven fibrous web, for example a carded web of viscose staple fibers.
- the basis weight of the absorbent layer may be in the range of 50-500g/m 2 , such as 100-400g/m 2 .
- the uncompressed thickness of the absorbent layer may be in the range of from 0.5mm to 10mm, such as 1mm to 4mm.
- the free (uncompressed) liquid absorbency measured for physiological saline may be in the range of 5 to 30 g/g at 25°C.
- the optional absorbent layer is a separate layer from the hydrogel layer in the wound dressings according to the present invention.
- the hydrogel layer and the optional absorbent layer are adjacent.
- the multilayer wound dressing according to the invention further comprises one or more protective cover sheets over the support sheet and any exposed hydrogel and/or adhesive.
- these may comprise one or more release-coated paper cover sheets.
- the dressing according to the present invention is sterile and packaged in a microorganism-impermeable container.
- the wound dressing or implant according to the present invention may also contain a medicament, in addition to the enzyme or enzymes entrapped in the hydrogel.
- Suitable medicaments will be well known to those of skill in the art and include antiseptics, such as povidone iodine or silver sulfadiazine; antibiotics such as enthromycin, neomycin, bacitracin, gentamycin, framycetin, thyrotrycin, polymyxin B, gramicidin, fusidic acid, chloramphemicol, tetracycline and its derivatives, minocycline chlortetracycline, hydrochloride, meclocyclin, penicillin and its derivatives, ampicillin or a cephalosporin; steroidal anti-inflammatories such as hydrocortisone, betamethasone, dexamethasone, prednisolone, and their derivatives; non- steroidal anti-inflammatories such as indomethacin, ketoprof
- the method method of making a wound dressing according to the present invention comprises the steps of: preparing a hydrogel premix comprising a synthetic hydrogel polymer precursor and an enzyme; applying a layer of the premix to a solid support; followed by polymerising the premix on the support to produce a layer of synthetic hydrogel material on the support, wherein an active enzyme is dispersed in the synthetic hydrogel material.
- the hydrogel premix is UV-curable and the step of polymerizing comprises curing the hydrogel with ultraviolet light.
- the hydrogels include the hydrogels based on ionic acrylate and acrylamide- derived monomers described in detail above. Suitable catalysts for the polymerisation may also be present.
- the hydrogel premix comprises an isocyanate-capped prepolymer
- said step of polymerising comprises allowing said prepolymer to react with a chain extending compound.
- Suitable chain extending compounds include water, diols and polyols, and diamines and polyamines.
- Suitable catalysts for the polymerisation may also be present.
- the hydrogel premix layer may be applied by spraying or, preferably, by a printing or transfer process.
- Apertures may be formed in the hydrogel layer for example by drilling with a hollow needle.
- the apertures may be formed by casting the support sheet in a mold having an array of projections corresponding to the apertures, followed by peeling the hydrogel layer from the mold and applying it in register to the support sheet.
- the hydrogel layer may be applied to an apertured substrate by the method of WO00/65143, the entire content of which is incorporated herein by reference. Specific embodiments of the present invention will now be described further, by way of example.
- a hydrogel layer for a dressing according to the present invention is prepared from the following materials:
- SPA 3-sulphylacrylate potassium salt
- PBS Phosphate buffered Saline
- the lactate oxidase was diluted in PBS with a dilution of 4 units/ml. This solution was stored at -20°C and defrosted when required.
- Hydrogen peroxide (H 2 0 2 ) generation assays utilise the reaction of H 2 0 2 with ortho- phenylene diamine (OPDA) in the presence of horseradish peroxidase.
- OPDA ortho- phenylene diamine
- the reaction mixture is initially colourless, but develops a yellow colouring with the presence of H 2 0 2 . It was the development of this colour that was measured quantitatively using the UV spectrophotometer.
- the method used trans-well plates with the hydrogel placed within the well; this was then lowered into a solution containing both the lactate and the assay solutions.
- This trans-well plates suspend the hydrogel in the solution above a membrane, which allows the free passage of lactate into, and hydrogen peroxide out of, the hydrogel, along with the assay solutions.
- the method also included three controls, one positive and two negative.
- the negative controls were: a) the hydrogel, containing no lactate oxidase, with the lactate and assay solutions, and b) the lactate and assay solutions on their own.
- the positive control used was the lactate and assay solution, but this time in conjunction with a sample of the lactate oxidase.
- the lactate oxidase solution used was of equal mass and dilution to that of the lactate oxidase found in the hydrogel to allow direct comparison.
- the test method comprised the following steps:
- trans-well inserts were then returned to their appropriate wells, and 2 units/ml lactate-oxidase control solutions was pipetted into its wells.
- Time point readings were taken using the UV spectrophotometer every half an hour, for the first two hours, and then every hour for the next three hours.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04743047A EP1635884A1 (en) | 2003-06-23 | 2004-06-23 | Hydrogel compositions comprising enzymes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0314604.0 | 2003-06-23 | ||
GB0314604A GB2403146B (en) | 2003-06-23 | 2003-06-23 | Method of making a wound dressing comprising lactate oxidase |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004112851A1 true WO2004112851A1 (en) | 2004-12-29 |
Family
ID=27637162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2004/002696 WO2004112851A1 (en) | 2003-06-23 | 2004-06-23 | Hydrogel compositions comprising enzymes |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1635884A1 (en) |
GB (1) | GB2403146B (en) |
WO (1) | WO2004112851A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005072783A1 (en) * | 2004-01-30 | 2005-08-11 | Insense Limited | Improvements in or relating to skin dressings |
WO2005072784A1 (en) * | 2004-01-30 | 2005-08-11 | Insense Limited | Wound dressings comprising hydrated hydrogels and enzymes |
WO2005110503A1 (en) * | 2004-04-30 | 2005-11-24 | Kimberly-Clark Worldwide, Inc. | Absorbent products with a linked enzyme treatment |
US7731954B2 (en) | 2002-04-24 | 2010-06-08 | Insense Limited | Wound dressings comprising hydrated hydrogels and enzymes |
US7927588B2 (en) | 2003-06-09 | 2011-04-19 | Archimed Llp | Skin dressings containing oxidoreductase enzyme |
TWI425959B (en) * | 2010-11-10 | 2014-02-11 | 私立中原大學 | Wound healing material and method for fabricating the same |
CN112980003A (en) * | 2021-04-16 | 2021-06-18 | 中国药科大学 | Natural polysaccharide based antibacterial hydrogel, preparation method and application |
CN114470297A (en) * | 2021-12-20 | 2022-05-13 | 山西医科大学 | Sugar-triggered response type wound quick-healing dressing and preparation method thereof |
CN115216132A (en) * | 2022-08-18 | 2022-10-21 | 常州大学 | GOx @ F68/F127 antibacterial hydrogel and preparation method thereof |
US20230226251A1 (en) * | 2022-01-17 | 2023-07-20 | Boock Engineering LLC | Wound care covering |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0609778D0 (en) * | 2006-05-17 | 2006-06-28 | Agt Sciences Ltd | Delivery means |
US8187984B2 (en) | 2006-06-09 | 2012-05-29 | Malden Mills Industries, Inc. | Temperature responsive smart textile |
JP2008057100A (en) * | 2006-08-29 | 2008-03-13 | Mmi-Ipco Llc | Temperature and moisture responsive smart textile |
US8389100B2 (en) | 2006-08-29 | 2013-03-05 | Mmi-Ipco, Llc | Temperature responsive smart textile |
JP2008057099A (en) | 2006-08-29 | 2008-03-13 | Mmi-Ipco Llc | Temperature responsive smart textile |
CN102137926A (en) * | 2006-12-13 | 2011-07-27 | Tgr生物科学私人有限公司 | Promoting ECM production by fibroblast cells and/or promoting migration of fibroblast cells in a biological system |
DK2338529T3 (en) * | 2009-12-24 | 2013-08-26 | Hartmann Paul Ag | Hydrogel matrix with improved adhesive properties |
DK2338528T3 (en) * | 2009-12-24 | 2013-08-26 | Hartmann Paul Ag | Hydrogel matrix with increased absorption capacity for liquids |
RU2438654C1 (en) * | 2010-09-16 | 2012-01-10 | Федеральное Государственное Унитарное Предприятие Научно-Производственный Центр "Фармзащита" | Hydrogel composition for treating burns |
CN103446618B (en) * | 2013-09-16 | 2015-11-18 | 河南科高辐射化工科技有限公司 | A kind of anti-bacterial hydrogel wound film and the wound-surface plaster adopting this film to make |
GB201509044D0 (en) | 2015-05-27 | 2015-07-08 | Systagenix Wound Man Ip Co Bv | Composition |
CN108676179B (en) * | 2018-05-17 | 2020-09-22 | 复旦大学 | Polyethylene glycol chemical hydrogel based on enzyme crosslinking and preparation method thereof |
CN109799528B (en) * | 2019-01-17 | 2022-08-19 | 中国辐射防护研究院 | Oxidized gel for sampling radioactive contaminated metal shallow layer and preparation method thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4576817A (en) * | 1984-06-07 | 1986-03-18 | Laclede Professional Products, Inc. | Enzymatic bandages and pads |
DE4026153A1 (en) * | 1990-08-17 | 1992-02-20 | Sebapharma Gmbh & Co | Wound bandage |
US5648252A (en) * | 1994-03-22 | 1997-07-15 | Israel Fiber Institute State Of Israel Ministry Of Industry And Trade | Supported polyionic hydrogels containing biologically active material |
WO2000065143A1 (en) * | 1999-04-23 | 2000-11-02 | First Water Limited | Process for coating a perforated substrate |
US20020018802A1 (en) * | 1998-03-27 | 2002-02-14 | Wolfgang Meyer-Ingold | Wound coverings for removal of interfering factors from wound fluid |
WO2002038097A1 (en) * | 2000-11-13 | 2002-05-16 | Johnson & Johnson Medical Limited | Hydrogel wound dressings |
WO2003090800A1 (en) * | 2002-04-24 | 2003-11-06 | Insense Limited | Wound dressings comprising hydrated hydrogels and enzymes |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0840597T3 (en) * | 1995-07-12 | 2004-01-26 | Cygnus Therapeutic Systems | hydrogel |
RU2264824C2 (en) * | 1999-06-18 | 2005-11-27 | Йон Браги БЬЯРНАСОН | Fish serine proteinases and their pharmaceutical and cosmetic application |
-
2003
- 2003-06-23 GB GB0314604A patent/GB2403146B/en not_active Expired - Fee Related
-
2004
- 2004-06-23 WO PCT/GB2004/002696 patent/WO2004112851A1/en active Application Filing
- 2004-06-23 EP EP04743047A patent/EP1635884A1/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4576817A (en) * | 1984-06-07 | 1986-03-18 | Laclede Professional Products, Inc. | Enzymatic bandages and pads |
DE4026153A1 (en) * | 1990-08-17 | 1992-02-20 | Sebapharma Gmbh & Co | Wound bandage |
US5648252A (en) * | 1994-03-22 | 1997-07-15 | Israel Fiber Institute State Of Israel Ministry Of Industry And Trade | Supported polyionic hydrogels containing biologically active material |
US20020018802A1 (en) * | 1998-03-27 | 2002-02-14 | Wolfgang Meyer-Ingold | Wound coverings for removal of interfering factors from wound fluid |
WO2000065143A1 (en) * | 1999-04-23 | 2000-11-02 | First Water Limited | Process for coating a perforated substrate |
WO2002038097A1 (en) * | 2000-11-13 | 2002-05-16 | Johnson & Johnson Medical Limited | Hydrogel wound dressings |
WO2003090800A1 (en) * | 2002-04-24 | 2003-11-06 | Insense Limited | Wound dressings comprising hydrated hydrogels and enzymes |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7731954B2 (en) | 2002-04-24 | 2010-06-08 | Insense Limited | Wound dressings comprising hydrated hydrogels and enzymes |
US7927588B2 (en) | 2003-06-09 | 2011-04-19 | Archimed Llp | Skin dressings containing oxidoreductase enzyme |
WO2005072783A1 (en) * | 2004-01-30 | 2005-08-11 | Insense Limited | Improvements in or relating to skin dressings |
WO2005072784A1 (en) * | 2004-01-30 | 2005-08-11 | Insense Limited | Wound dressings comprising hydrated hydrogels and enzymes |
WO2005110503A1 (en) * | 2004-04-30 | 2005-11-24 | Kimberly-Clark Worldwide, Inc. | Absorbent products with a linked enzyme treatment |
US7928282B2 (en) | 2004-04-30 | 2011-04-19 | Kimberly-Clark Worldwide, Inc. | Absorbent products with a linked enzyme treatment |
TWI425959B (en) * | 2010-11-10 | 2014-02-11 | 私立中原大學 | Wound healing material and method for fabricating the same |
CN112980003A (en) * | 2021-04-16 | 2021-06-18 | 中国药科大学 | Natural polysaccharide based antibacterial hydrogel, preparation method and application |
CN114470297A (en) * | 2021-12-20 | 2022-05-13 | 山西医科大学 | Sugar-triggered response type wound quick-healing dressing and preparation method thereof |
US20230226251A1 (en) * | 2022-01-17 | 2023-07-20 | Boock Engineering LLC | Wound care covering |
CN115216132A (en) * | 2022-08-18 | 2022-10-21 | 常州大学 | GOx @ F68/F127 antibacterial hydrogel and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
GB0314604D0 (en) | 2003-07-30 |
EP1635884A1 (en) | 2006-03-22 |
GB2403146B (en) | 2007-07-11 |
GB2403146A (en) | 2004-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004112851A1 (en) | Hydrogel compositions comprising enzymes | |
ES2915475T3 (en) | wound dressing | |
CA2931174C (en) | No-emitting medical dressing comprising an no-generating module and a radiation-emitting module | |
US10688215B2 (en) | Flexible hydrogel wound dressings | |
US8871992B2 (en) | Multilayer compositions and dressings | |
US6592890B1 (en) | Conveyance of anti-infective activity to wound dressings | |
JP5483365B2 (en) | Improvement of reduced pressure dressing coated with biomolecules | |
EP3068448B1 (en) | Multilayer composition | |
US7368128B2 (en) | Controlled release dressing for enzymatic debridement of necrotic and non-viable tissue in a wound | |
AU2004244803B2 (en) | Skin dressings containing oxidoreductase enzyme | |
US20050159695A1 (en) | Controlled release therapeutic wound dressings | |
EP2313118B1 (en) | Compositions for use as or in wound dressings | |
JP2007519696A (en) | Improvements in or relating to skin dressings | |
JP2004520096A (en) | Hydrogel wound dressing | |
US20110135726A1 (en) | Hydrogel composites and wound dressings | |
JP2022523780A (en) | Antibacterial dressings, dressing components, and methods | |
US10076586B2 (en) | Wound dressings | |
WO2009019485A2 (en) | A wound dressing | |
GB2433205A (en) | Wound dressing comprising a strong cation exchange resin | |
Turner | Interactive dressings used in the management of human soft tissue injuries and their potential in veterinary practice | |
US20240157017A1 (en) | A medical dressing comprising a bacteriostatic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004743047 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004743047 Country of ref document: EP |